Urea Cycle Disorders Treatment Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Urea Cycle Disorders Treatment Market Growth in 2025?
The market size for treatment of urea cycle disorders has been on a consistent growth trajectory in the past few years. The projected growth indicates a rise from $1.33 billion in 2024 to $1.39 billion in 2025, representing a compound annual growth rate (CAGR) of 4.0%. Factors contributing to this historic growth trend include increased awareness and education, enhancements in newborn screening processes, the establishment of patient support networks, and the setting of care standards guidelines.
What Is the Forecast for the Urea Cycle Disorders Treatment Market Size Through 2029?
Anticipations show consistent expansion in the market size for urea cycle disorders treatment over the next few years. The market value is projected to reach $1.65 billion by 2029, growing at a 4.5% compound annual growth rate (CAGR). Multiple factors contribute to this anticipated growth during the forecasted period, including breakthroughs in enzyme replacement therapy, extensive newborn screening programs, heightened research collaborations, proliferation of therapeutic choices, and the inclusion of telemedicine and remote care. The forecast period will also see significant trends such as improved gene editing technologies, awareness and advocacy campaigns, strategies in regenerative medicine, comprehensive safety and efficacy studies, and tailored nutritional therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12237&type=smp
What are the Key Market Players in Urea Cycle Disorders Treatment Market and How They’re Evolving?
Major companies operating in the urea cycle disorders treatment market include Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc., Abbott Laboratories, Mead Johnson & Company, LLC, Horizon Therapeutics Plc, Nestlé S.A., Danone S.A., Biophone, Relief Therapeutics Holding AG, TheraTriage, Genomatica, Protalix BioTherapeutics, Erytech Pharma, 4D Pharma, Synlogic, Amicus Therapeutics, Sobi, Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Medpace Holdings, Inc., Celerion, and PTC Therapeutics
What Are the Primary Growth Drivers in the Urea Cycle Disorders Treatment Market?
The increase in the occurrence of urea cycle disorders is predicted to boost the urea cycle disorders treatment market’s expansion in the future. Urea cycle disorder is a metabolic disorder that is inherited and arises from defects in necessary liver enzymes or transport molecules for ammonia removal from the bloodstream. The surge in urea cycle disorders is related to genetic abnormalities. If an accumulation of ammonia is diagnosed as a urea cycle disorder (UCD), a tailor-made treatment plan involving dietary regulation, medication, and routine checks can be adopted to manage and mitigate its adverse effects. As an illustration, StatPearls Publishing LLC, an American medical education library, noted in April 2023 that the prevalence of urea cycle disorders caused by ornithine transcarbamylase deficiency was 1 in 140,000 individuals. Moreover, in September 2022, as per Lecturio, a digital medical education platform based in Germany, the urea cycle disorders (UCDs) occur in an estimated 1 in every 35,000 live births worldwide and 1 in 8,200 live births in the USA, resulting in an annual incidence of approximately 113 new cases in the USA and around 149 in Europe. Consequently, the increasing incidence of urea cycle disorders is fueling the growth of the urea cycle disorders treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12237&type=smp
What Are the Leading Segments in the Global Urea Cycle Disorders Treatment Industry?
The urea cycle disorders treatment market covered in this report is segmented –
1) By Treatment: Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Other Treatments
2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC), Argininosuccinate Synthetase (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1)
3) By Route of Administration: Oral, Injectables
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Amino Acid Supplements: Arginine Supplements, Citrulline Supplements, Other Essential Amino Acids
2) By Sodium Phenylbutyrate: Powder Form, Tablet Form
3) By Glycerol Phenylbutyrate: Oral Solutions, Other Forms
4) By Sodium Benzoate: Intravenous Solutions, Oral Formulations
5) By Other Treatments: Liver Transplantation, Dietary Modifications, Enzyme Replacement Therapy, Other Supportive Therapies
What Are the Key Market Trends in the Urea Cycle Disorders Treatment Industry?
The emergence of product innovation has been identified as a fundamental trend gaining traction in the urea cycle disorder treatment market. Leading companies in the field are increasingly focusing on generating exciting and innovative products to fortify their standing in this market. For example, in September 2022, Medunik USA, a pharmaceutical firm based in the US, introduced Pheburane oral pellets, a distinctive and flavor-concealing formulation of sodium phenylbutyrate (NaPB) intended for the enduring control of specified urea cycle disorders. This prescription medication, used alongside a specific dietary plan, treats urea cycle disorders (UCDs) in adults and children, particularly deficiencies in carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinate synthetase (AS). It is administered with a reusable, calibrated dosing spoon that accompanies each package; unlike other NaPB variations, it doesn’t require mixing or oral ingestion. Pheburane can be taken with a snack or meal, sprinkled on a spoonful of apple sauce or carrot puree, and washed down with water, fruit juice, or protein-free infant formula.
Access The Full Report Here:
What Is the Regional Outlook for the Urea Cycle Disorders Treatment Market?
North America was the largest region in the urea cycle disorders treatment market in 2024. The regions covered in the urea cycle disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12237
This Report Delivers Insight On:
1. How big is the urea cycle disorders treatment market, and how is it changing globally?
2. Who are the major companies in the urea cycle disorders treatment market, and how are they performing?
3. What are the key opportunities and risks in the urea cycle disorders treatment market right now?
4. Which products or customer segments are growing the most in the urea cycle disorders treatment market?
5. What factors are helping or slowing down the growth of the urea cycle disorders treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
